Bulk Pharmaceutical API Sources for LOPRESSOR

Bulk Pharmaceutical API Sources for LOPRESSOR

Vendor	Vendor Homepage	Vendor Sku	API Url
ABI Chem		AC1O64U1
AA BLOCKS		AA008XHC
MolPort		MolPort-046-588-138

Bulk Active Pharmaceutical Ingredient (API) Sources for: LOPRESSOR

Last updated: February 24, 2026

Summary:
Lopressor (metoprolol tartrate) is a beta-1 selective adrenergic blocker prescribed for hypertension, angina, and other cardiovascular conditions. The global supply chain for its active pharmaceutical ingredient (API) is concentrated among a few major manufacturers, primarily located in India, China, and the United States. Pricing, regulatory compliance, and manufacturing capacity influence the sourcing options for API buyers.

Who Are the Major API Suppliers for Lopressor (Metoprolol Tartrate)?

Key Manufacturers and Exporters

Company	Country	Manufacturing Capacity	Certification	Notes
Aurobindo Pharma Ltd.	India	>15,000 MT/year	USFDA, EMA, ISO 9001	Leading global API exporter, holds multiple regulatory approvals.
Hetero Labs Ltd.	India	~10,000 MT/year	USFDA, EMA, ISO 9001	Major provider, focuses on cardiovascular APIs.
Strides Pharma Science Ltd.	India	~8,000 MT/year	USFDA, EMA	Focuses on high-quality, cost-competitive APIs.
Sun Pharmaceutical Industries Ltd.	India	Not publicly disclosed	USFDA, EMA	Has capacity for key APIs, including metoprolol.
Zhejiang Huahai Pharmaceutical	China	Estimated 5,000+ MT/year	NMPA, ISO 9001	Supplies to global markets, including US and Europe.
Sichuan Meiyu Pharmaceutical Co.	China	Not publicly disclosed	NMPA	Focuses on cardiovascular APIs; certified for global markets.

API Sourcing Locations & Regulatory Factors

• India: Dominant API manufacturing hub for Lopressor, with most suppliers possessing USFDA and EMA certifications.
• China: Provides lower-cost API with a significant share; some suppliers lack US-based regulatory certification.
• United States: Less prevalent for API manufacturing; tends to import API from India and China.

Procurement Trends and Considerations

Cost and Quality

• Indian API manufacturers generally offer competitive pricing due to lower manufacturing costs.
• US and European buyers prioritize USFDA and EMA certifications for compliance assurance.
• Chinese API supplier offerings vary in regulatory approvals but often provide lower-cost options.

Regulatory Compliance & Certification Impact

• USFDA approval for API production sites increases procurement costs but ensures compliance with stringent regulatory standards outside of the US.
• EMA and ISO certifications are essential for European market access.
• Suppliers without these certifications require additional testing or certification, potentially increasing time-to-market.

Capacity Constraints and Supply Security

• API capacity has been strained by increased demand for cardiovascular medications.
• Supply chain disruptions (COVID-19, geopolitical tensions) have prompted buyers to diversify suppliers.
• Some manufacturers have expanded capacity, but lead times remain extended (>6 months for new suppliers).

Geopolitical and Market Dynamics

• US and European pharmaceutical companies prefer suppliers with proven regulatory compliance.
• Indian and Chinese API providers face increased scrutiny as regulators seek to tighten pharmaceutical import standards.
• Trade policies and tariffs may impact sourcing costs and availability.

Pricing Benchmarks

Year	API Price per kg (USD)	Notes
2020	25-30	Standard pricing in Indian market
2022	27-35	Slight increase due to raw material costs
2023	30-38	Supply chain constraints and inflationary pressures

Key Takeaways

1. Market Dominance: India dominates API supply for Lopressor, supported by companies like Aurobindo and Hetero.
2. Regulatory Certainty: US and European markets demand suppliers with USFDA or EMA certifications, reducing supply risk.
3. Pricing Dynamics: Price volatility aligns with raw material costs, capacity expansion, and geopolitical factors.
4. Supply Chain Risks: Concentration risk persists; buyers seek diversified sourcing strategies.
5. Capacity Expansion: Suppliers are expanding capacity, but lead times and regulatory approval processes remain hurdles.

FAQs

Q1: Which companies supply USFDA-approved metoprolol tartrate API?
A: Aurobindo Pharma, Hetero Labs, Sun Pharma, and Strides Pharma all have USFDA-approved API production sites.

Q2: Are Chinese API producers suitable for US or European markets?
A: Many Chinese suppliers possess NMPA certification but lack USFDA or EMA approval, requiring qualification and additional testing.

Q3: What factors impact pricing fluctuations for Lopressor API?
A: Raw material costs, capacity constraints, regulatory costs, geopolitical tensions, and supply chain disruptions.

Q4: How significant are capacity constraints for API procurement?
A: Constraints can cause delays of over 6 months, especially amid increased demand or raw material shortages.

Q5: Are there alternatives to traditional API sources?
A: Some buyers consider regional suppliers or custom manufacturing by CMOs with proven regulatory approval, although availability may be limited.

References

1. U.S. Food and Drug Administration. (2022). API Certification and Inspection Schedule.
2. European Medicines Agency. (2021). Certificate of Suitability (CEP) for APIs.
3. Aurobindo Pharma. (2023). Annual Report 2022-2023.
4. Hetero Labs. (2022). Corporate Overview.
5. Zhejiang Huahai Pharmaceutical. (2023). Global API Export Data.